1. Market Research
  2. > Healthcare
  3. > Health Services Market Trends
Corneal Endothelial Dystrophy (CED) – Epidemiology Forecast—2030

Corneal Endothelial Dystrophy (CED) – Epidemiology Forecast—2030

  • December 2020
  • 68 pages
  • ID: 5993612
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

‘Corneal Endothelial Dystrophy (CED) – Epidemiology Forecast—2030’ report delivers an in-depth understanding of the Corneal Endothelial Dystrophy, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Corneal Endothelial Dystrophy Disease Understanding
Corneal dystrophies are a group of rare genetic diseases that affect the cornea, the front part of the eye. There are more than 20 types, each with different symptoms, all-cause a build-up of foreign material in one or more layers of the cornea. Corneal Endothelial Dystrophy or Fuchs’ endothelial dystrophy is a defect of the endothelial layer of the cornea. It can be either sporadic or inherited in an autosomal dominant manner. Fuchs’ endothelial dystrophy is characterized by the swelling of the cornea, which leads to glare, halo, and reduced visual acuity. In some cases, it can lead to corneal blindness.
Fuchs endothelial dystrophy (FED) or CED is characterized by an asymmetrical, bilateral, slowly progressive edema of the cornea in elderly patients and is found to be more prominent in females as compared to males. Deposits called guttae are generally detectable during an eye exam. They usually form in the middle of the cornea and eventually spread throughout the cornea. These guttae contribute to the ongoing cell death within the cornea, leading to worsening vision problems. Tiny blisters may develop on the cornea, which can burst and cause eye pain.

Corneal Endothelial Dystrophy Epidemiology
The Corneal Endothelial Dystrophy epidemiology division provides insights about the historical and current patient pool, along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the prevalent patient pool and their trends along with assumptions undertaken.

Key Findings
The total prevalent cases of Corneal Endothelial Dystrophy patients are increasing in 7MM during the study period, i.e. 2017–2030.
The disease epidemiology covered in the report provides historical as well as forecasted Corneal Endothelial Dystrophy symptoms epidemiology segmented as the Total Prevalent cases of Corneal Endothelial Dystrophy, Gender-specific cases of Corneal Endothelial Dystrophy, Age-specific cases of Corneal Endothelial Dystrophy, and Type-specific cases of Corneal Endothelial Dystrophy. The report includes the prevalent scenario of Corneal Endothelial Dystrophy symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Corneal Endothelial Dystrophy Epidemiology
The epidemiology segment also provides the Corneal Endothelial Dystrophy epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total prevalent cases of Corneal Endothelial Dystrophy associated in 7MM countries were 6,194,906 in 2017.
• As per the estimates, the United States has the largest prevalent population of Corneal Endothelial Dystrophy.
• Among the EU5 countries, Germany had the highest prevalent cases of Corneal Endothelial Dystrophy, followed by Italy. On the other hand, the UK had the lowest prevalent cases with 1,472,742 cases in 2017.

Scope of the Report
• The Corneal Endothelial Dystrophy report covers a detailed overview explaining its causes, symptoms, and classification, pathophysiology, diagnosis, and treatment patterns.
• The Corneal Endothelial Dystrophy Epidemiology Report and Model provide an overview of the risk factors and global trends of Corneal Endothelial Dystrophy in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
• The report provides insight into the historical and forecasted patient pool of Corneal Endothelial Dystrophy in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
• The report helps recognize the growth opportunities in the 7MM concerning the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of Corneal Endothelial Dystrophy.
• The report provides the segmentation of the Corneal Endothelial Dystrophy epidemiology by Prevalent Cases of Corneal Endothelial Dystrophy in 7MM.
• The report provides the segmentation of the Corneal Endothelial Dystrophy epidemiology by Gender-specific Prevalent Cases of Corneal Endothelial Dystrophy in 7MM.
• The report provides the segmentation of the Corneal Endothelial Dystrophy epidemiology by Age-Specific Prevalent Cases of Corneal Endothelial Dystrophy in 7MM.
• The report provides the segmentation of the Corneal Endothelial Dystrophy epidemiology by Severity-Specific Prevalent Cases of Corneal Endothelial Dystrophy in 7MM.

Report Highlights

• 11-Year Forecast of Corneal Endothelial Dystrophy epidemiology
• 7MM Coverage
• Total Prevalent Cases of Corneal Endothelial Dystrophy
• Prevalent Cases according to segmentation: Gender-specific cases of Corneal Endothelial Dystrophy
• Prevalent Cases according to segmentation: Age-specific cases of Corneal Endothelial Dystrophy
• Prevalent Cases according to segmentation: Type-specific cases of Corneal Endothelial Dystrophy

KOL Views
We interview KOLs, and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
• What will be the growth opportunities in the 7MM for the patient population of Corneal Endothelial Dystrophy?
• What are the key findings of the Corneal Endothelial Dystrophy epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017–2030)?
• What would be the total number of patients of Corneal Endothelial Dystrophy across the 7MM during the forecast period (2017–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017–2030)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017–2030)?
• What are the disease risk, burden, and unmet needs of the Corneal Endothelial Dystrophy?
• What are the currently available treatments of Corneal Endothelial Dystrophy?

Reasons to buy
The Corneal Endothelial Dystrophy epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global Corneal Endothelial Dystrophy market
• Quantify patient populations in the global Corneal Endothelial Dystrophy market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Corneal Endothelial Dystrophy therapeutics in each of the markets covered
• Understand the magnitude of Corneal Endothelial Dystrophy population by its prevalent cases
• Understand the magnitude of Corneal Endothelial Dystrophy population by its Gender-specific cases
• Understand the magnitude of Corneal Endothelial Dystrophy population by its Age-specific cases
• Understand the magnitude of Corneal Endothelial Dystrophy population by its Severity-specific cases
• The Corneal Endothelial Dystrophy epidemiology report and model were written and developed by Masters and PhD level epidemiologists
• The Corneal Endothelial Dystrophy Epidemiology Model developed is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2017–2030
The late-onset form of Fuchs endothelial dystrophy is a common condition, affecting people over the age of 40 in the United States. This disease typically starts in the 30s and 40s, but many people with Fuchs’ dystrophy do not develop symptoms until they reach their 50s or 60s. The early-onset variant of Fuchs endothelial dystrophy is comparatively rare, although the exact prevalence is unknown.
Several prevalence studies have placed the prevalence in the United States between 4% and 7% of people aged 40 and above, the prevalence being higher in the Caucasian population. In Europe, 4.5–9% of people aged 40 and above are expected to suffer from Fuchs’ dystrophy. However, the Japanese prevalence estimates are lower. Kitagawa et al. (2002) conducted a Japanese study with 299 subjects and found the prevalence to be 3.7%.
Moreover, it must be noted that all these studies use corneal guttata as a surrogate for early-stage Fuchs’ disease. According to our primary market research, most of these patients would have very mild or no symptoms, which might not need intervention; approximately 5% of patients with corneal guttata become symptomatic and have disease progression that warrants surgical intervention.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Phenylketonuria - Epidemiology Forecast-2030

  • $ 3750
  • February 2021
  • 100 pages

‘Phenylketonuria—Epidemiology Forecast–2030’ report delivers an in-depth understanding of the PKU, historical and forecasted epidemiology as well as the PKU trends in the United States, EU5 (Germany, ...

  • Spain
  • France
  • Endocrine Disease
  • Epidemiology
  • Industry analysis

ref:plp2020

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on